MASLD and MASH: Prioritising a Global Public Health Threat
Join Economist Impact for ‘MASLD and MASH*: prioritising a global public health threat’, a liver health policy event alongside the UN General Assembly (UNGA), supported by the Barcelona Institute for Global Health (ISGlobal).
*MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis)
Topics include:
- What are the social and economic consequences of leaving MASLD and MASH unaddressed?
- How could awareness around MASLD and MASH be improved to encourage more action by governments, healthcare providers and civil society?
- How can a more cohesive community of practice around MASLD and MASH be developed, nurtured and supported?
- What type of policies can be put in place to reduce the environmental, social, economic and human contributors to MASLD?
Speakers include:
- Keynote: H.E. Hanan Mohamed Al Kuwari, minister of public health, Qatar
- Keynote: Werner H. Obermeyer, director, WHO Office at the United Nations
- Vanessa Garcia Larsen, unit chief on risk factors and nutrition, department of noncommunicable diseases and mental health, Pan American Health Organization
- Jeffrey Lazarus, head of public health liver group, ISGLOBAL; professor of global health, CUNY SPH; chair, Healthy Livers Healthy Lives Coalition
- Johanna Ralston, ceo, World Obesity Federation
- Arun J. Sanyal, director, Stravitz-Sanyal institute for liver disease and metabolic health, Virginia Commonwealth University School of Medicine
The event is supported financially by Novo Nordisk, Boehringer Ingelheim, Echosens, The CUNY Graduate School of Public Health and Health Policy and the CUNY SPH Foundation.